Lilly

Elan cuts 104 jobs

Friday, July 15, 2011 10:13 AM

Following the recent decision to sell its drug manufacturing unit to Alkermes for $960 million, Elan is eliminating 104 jobs from a Pennsylvania facility that is part of the deal, according to a notice filed with the Pennsylvania Department of Labor.

More... »

Novartis considers IPO in China

Wednesday, July 13, 2011 10:10 AM

Swiss drug maker Novartis is considering a possible initial public offering in China, joining a growing list of multinationals eyeing a listing on Shanghai's planned international board, two people with knowledge of the situation told Reuters.

More... »

FDA eases rules for Alzheimer’s experiments to speed new treatments for dementia

Tuesday, July 12, 2011 12:35 PM

The FDA is making it easier to test new Alzheimer’s drugs, hoping to speed progress toward new treatments for the mind-robbing disease, according to an Associated Press report.

More... »

Study results support BYDUREON’s NDA

Friday, July 8, 2011 12:21 PM

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced results from QT (tQT) study of exenatide to increase the QT interval across a wide range of plasma concentrations. The study was conducted to satisfy a requirement by the FDA in support of the New Drug Application (NDA) for BYDUREON (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes.

More... »

Lilly pitches plan to overcome key patent losses

Friday, July 8, 2011 10:15 AM

Eli Lilly, only months away from losing patent protection for its top-selling drug, told investors the keys to overcoming this and other patent losses lie in its labs and emerging markets including China, according to Mercury News.

More... »

Former Pfizer research chief wary of R&D strategy

Thursday, July 7, 2011 10:02 AM

Pfizer may have won over shareholders with its recent decision to pare back R&D spending, but it could be shortchanging them in the long run, Pfizer’s former research chief told Reuters.

More... »

CEO says Eli Lilly is committed to R&D

Thursday, June 30, 2011 01:14 PM

Eli Lilly is committed to spending what it takes to come up with innovative drugs over the long term, its chief executive said, even though the company's earnings are expected to tumble over the next three years.

More... »

Lilly and investor group form new critical-care company BioCritica

Monday, May 23, 2011 02:17 PM

Eli Lilly has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica, a newly-formed and privately held biotechnology company. BioCritica, based in Central Indiana, will initially focus on the continued U.S. development and commercialization of Xigris (drotrecogin alfa (activated)), Lilly's medicine for severe sepsis. BioCritica intends to ultimately build a broad portfolio of innovative, hospital-based critical care medicines.

More... »

Astellas adds four to team

Tuesday, May 3, 2011 12:33 PM

Astellas Pharma Global Development, a subsidiary of Tokyo-based Astellas Pharma, welcomes four new industry leaders to its team.

More... »

Boehringer/Lilly's diabetes drug receives FDA approval

Tuesday, May 3, 2011 12:20 PM

Boehringer Ingelheim and its partner Eli Lilly report that the FDA has approved their once-daily type II diabetes pill linagliptin (Tradjenta).

More... »